secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2026-06-23T21:16:01+00:00
Accession:  0001193125-26-279778
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics annual meeting approves 2026 equity plan, re-elects director
---------------------------------------------------------------------------

- Stockholders approved the 2026 Equity and Incentive Plan with 2.62M for, 297k against; 2.06M shares available, including 2M new shares and 61,968 from prior plan.
- Pete O'Heeron re-elected as Class III director with 2.80M for, 119k against; Stacy Coen did not stand for re-election.
- Ratified WithumSmith+Brown as auditor for FY 2026 with 4.11M for, 43k against.
- Approved issuance of up to 2.27M shares from March SPA warrants and 159k shares from H.C. Wainwright engagement letter.
- 4.17M shares represented out of 6.83M eligible; all four proposals passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526279778/0001193125-26-279778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526279778/fblg-20260622.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-279778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer